Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 11/20 | 0.61 |
| ▸ | HTR2B | P41595 | 11/20 | 0.61 |
| ▸ | KDM1A | O60341 | 5/20 | 0.48 |
| ▸ | MAOB | P27338 | 4/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.48 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.48 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 8/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2830644 | 1.00 | HTR2C (0.61) | HTR2CHTR2BKDM1AMAOBKCNH2 | |
| SCHEMBL2826045 | 0.84 | HTR2C (0.66) | HTR2CHTR2BKDM1AMAOBKCNH2 | |
| SCHEMBL4893904 | 0.84 | HTR2C (0.66) | HTR2CHTR2BKDM1AMAOBKCNH2 | |
| SCHEMBL2826042 | 0.84 | HTR2C (0.66) | HTR2CHTR2BKDM1AMAOBKCNH2 | |
| SCHEMBL7026793 | 0.81 | HTR2C (0.59) | HTR2CHTR2BHTR2ASLC6A2SLC6A4 | |
| SCHEMBL13113993 | 0.81 | HTR2C (0.59) | HTR2CHTR2BMAOBHTR2ASLC6A2 | |
| SCHEMBL25262357 | 0.80 | HTR2C (0.59) | HTR2CHTR2BKDM1AMAOBKCNH2 | |
| SCHEMBL16685785 | 0.77 | HTR2C (0.56) | HTR2CHTR2BKDM1AMAOBKCNH2 | |
| SCHEMBL6250305 | 0.77 | HTR2C (0.63) | HTR2CHTR2BKDM1AMAOBHTR2A | |
| SCHEMBL22334928 | 0.76 | HTR2C (0.66) | HTR2CHTR2BKDM1AMAOBKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9108948-B2 | Cyclopropyl amine derivatives | ABBVIE INC. (US) | 2015-08-18 | — | — | US | disclosed |
| EP-2049472-B1 | CYCLOPROPYL AMINE DERIVATIVES AS HISTAMIN H3 RECEPTOR MODULATORS | ABBVIE BAHAMAS LTD (BS) | 2015-01-21 | — | — | EP | disclosed |
| US-8829041-B2 | Cyclopropyl amine derivatives | ABBVIE INC. (US) | 2014-09-09 | — | — | US | disclosed |
| EP-2231631-A1 | CYCLOPROPYL AMINE DERIVATIVES | Abbott Laboratories (US) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009079225-A1 | CYCLOPROPYL AMINE DERIVATIVES | ABBOTT LABORATORIES (US) | 2009-06-25 | — | — | WO | disclosed |
| EP-2049472-A2 | CYCLOPROPYL AMINE DERIVATIVES AS HISTAMIN H3 RECEPTOR MODULATORS | Abbott Laboratories (US) | 2009-04-22 | — | — | EP | disclosed |
| US-20080242653-A1 | Cyclopropyl amine derivatives | ABBVIE INC. | 2008-10-02 | — | — | US | disclosed |
| US-20080021081-A1 | e.g. 4'-2-{[(2S)-2-methylpyrrolidin-1-yl]methyl}cyclopropyl)-1,1'-biphenyl-4-carbonitrile; histamine-3 receptor ligand; neuroleptic agent, neurodegenerative diseases, cognition activator; attention-deficit hyperactivity disorder, schizophrenia, Alzheimer's disease, epilepsy, seizures, allergic rhinitis | ABBVIE INC. | 2008-01-24 | — | — | US | disclosed |
| WO-2007150010-A2 | CYCLOPROPYL AMINE DERIVATIVES AS HISTAMIN H3 RECEPTOR MODULATORS | ABBOTT LABORATORIES (US) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021081-A1 | e.g. 4'-2-{[(2S)-2-methylpyrrolidin-1-yl]methyl}cyclopropyl)-1,1'-biphenyl-4-carbonitrile; histamine-3 receptor ligand; neuroleptic agent, neurodegenerative diseases, cognition activator; attention-deficit hyperactivity disorder, schizophrenia, Alzheimer's disease, epilepsy, seizures, allergic rhinitis | HRH4, HRH3, HNMT | HTR2C 13/4885HTR2B 22/4885KDM1A 669/4885 |
| US-20080242653-A1 | Cyclopropyl amine derivatives | HRH3, HRH4, HRH2 | HTR2C 213/4885HTR2B 121/4885KDM1A 1513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.